Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

Alzheimer's impacts millions globally, with projections of 100 million affected by 2050 and costs of 800 billion dollars ...

Alzheimer's disease affects the brain in tragic and seemingly irreversible ways, but a new study gives hope that its ...

Alzheimer’s disease erodes memory, independence, and life. A new study finds that Cathepsin B, a protein released by active ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

La Plata County resident Al Jason, 78, has spent a lifetime caring for others. After his Alzheimer’s disease diagnosis last ...

Grief is often associated with death, says Paul Rado, 71, of La Plata County. But as he cares for his wife Jackie, 77, who ...

New guidelines for blood-based biomarkers, the impact of hormone replacement therapy and risks for cognitive decline with red ...

On Dec. 30, the Caddo Parish Sheriff’s Office (CPSO) asks for the public’s help in finding Kindley Thompson, 81, from Vivian, ...

Former Sen. Jon Kyl (R-Ariz.), who served in Congress for more than 25 years, announced Tuesday that he has dementia. Kyl, 83 ...

The FDA accepted Axsome’s supplemental New Drug Application (sNDA) for AXS-05, setting a target action date of April 30, 2026. The priority review designation shortens the FDA’s review timeline from ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.